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The immunodepleting effects of alemtuzumab on peripheral blood progenitor cell (PBPC) grafts for stem cell
transplantation need to be better deﬁned. The optimal graft cell concentration, antibody dose, need for
complement, and whether alemtuzumab is infused with the graft during transplantation remain unclear.
PBPC from 6 normal allogeneic stem cell donors harvested by apheresis were ﬁrst quantitated and the cellular
content deﬁned by ﬂow cytometry. Mononuclear cells were then incubated with incremental concentrations
of alemtuzumab (.00001, .0001, .001, and .01 mg/mL) for 30 minutes at 20C or in cell dose responses with 1,
5, and 10  106 mononuclear cells/mL added to a ﬁxed dose of .001 mg/mL of alemtuzumab with or without
a source of complement. Cells were enumerated and analyzed by ﬂow cytometry before and after exposure to
alemtuzumab. To determine the presence of unbound anti-CD52, the supernatant of the cell dose responses
were tested using the ELISA assay. Selected CD34þ lineage-negative cells were incubated with antibody at the
same working concentrations and conditions and cultured in granulocyte-macrophage colony-forming unit
assay. The colony numbers were compared with control cultures devoid of the antibody. Incremental
concentrations of alemtuzumab led to a signiﬁcant (2 log) reduction in CD3, CD4, and CD8 populations, which
plateaued at .001 mg/mL. Addition of complement led to a further signiﬁcant reduction in the CD4 and CD8
cells. The maximum CD4 (3 log) and CD8 (2 log) cell death was obtained at 10  106 cells/mL. Analysis of
supernatants for soluble alemtuzumab by ELISA showed a signiﬁcant reduction in the free antibody
concentration when the cell number was increased from 1 to 10  106 cells/mL implying utilization/binding
of the antibody by target cells. Incremental concentrations of alemtuzumab did not affect the number of
granulocyte-macrophage colony-forming units. Alemtuzumab depletes all cells expressing the CD52 antigen
and has higher activity on CD3, CD8, and particularly on CD4 cells, which are depleted in excess of 2 logs.
From this study, we were able to derive that the optimal cell kill in the graft without detectable free alem-
tuzumab in the supernatant can be achieved with 1 mg of antibody per 100 mL containing 10  109 cells and
active complement (AB serum).
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
High-dose chemoradiotherapy followed by the allogeneic
transplantation of hematopoietic stem cells from either bone
marrow or peripheral blood is widely used in the treatment
of malignant and nonmalignant hematological diseases.
However, these procedures are frequently associated with
the development of acute and chronic graft-versus-host
disease (GVHD), which is thought to occur as a result of
activation of donor T cells in the graft followed by a cytotoxic
attack on host tissues, affecting particularly the liver, skin,
and gastrointestinal tract [1]. Alemtuzumab is a humanized
murine anti-CD52 antibody used either in vivo (injected
intravenously) or ex vivo (to purge grafts) and has been
shown to reduce both the incidence and severity of GVHD
[2-6]. The CD52 antigen is found on the surface of most
lymphocytes, macrophages, monocytes, neutrophils, andedgments on page 1759.
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13.10.001eosinophils in relatively high density [7-9]. Although some
studies reject its expression on hematopoietic stem cells
[8,10,11], others have proven its presence both on CD34þ
hematopoietic cells [11] and on CD34þ cells in the blastic
phase of chronic myeloid leukemia [12].
The originating anti-CD52 molecule was a murine IgM
isotype that had potent complement-dependent cell cyto-
toxicity. The IgG switch variant was shown to effectively
deplete T cells and has also been used in clinical studies for
the prevention of GVHD [3,13,14]. Campath 1H (alemtuzu-
mab) is the humanized version that causes immune cell
killing by both complement-dependent cell cytotoxicity and
antibody-dependent cell cytotoxicity (ADCC) [15,16]. Pre-
treatment of transplant recipients with alemtuzumab (100
to120 mg) has been associated with improved engraftment
(due to reduction of patients’ T cells able to reject the graft)
and reduction in acute and chronic GVHD. However, its
extended post-transplant survival in patients’ circulation led
to delayed immune reconstitution due to its cytotoxic effect
on emerging naïve T cells, resulting in high rates of oppor-
tunistic infections and higher treatment-related mortality
[17,18]. In addition, an increase in the relapse rate of certainTransplantation.
N. Novitzky et al. / Biol Blood Marrow Transplant 19 (2013) 1753e17591754hematological malignancies such as chronic myelogenous
leukemia has been reported [17].
Alemtuzumab has also been tested in laboratory studies
ex vivo to immunodeplete cell suspensions, but there is less
information on the effects of this molecule when added to
peripheral blood cytokine mobilized progenitor cells. We
previously described that after ex vivo treatmentof graftswith
anti-CD52, the frequency and severity of GVHD was reduced.
In an analysis of 120 patients undergoing allogeneic stem cell
transplantation with Campath 1Getreated grafts or alemtu-
zumab “in the bag,” we showed an inverse relationship
between the dose of the antibody used and favorable outcome
[2]. Because most hematological cells express CD52 antigen
and therefore are targeted by the antibody, it remains unclear
if exhaustion of the antibody by other competing nonimmune
CD52þ cells, such as myeloid progenitor cells present in the
bone marrow or the peripheral blood progenitor cell (PBPC)
graft, may have an impact on the composition of the graft and
ultimately on the incidence and severity of GVHD. Alterna-
tively, if a largerdose of the antibody is added to the graft, then
the remaining soluble alemtuzumab in the cell suspension
could have a signiﬁcant in vivo role because the whole
transplant product is usually infused without washing off the
antibody. Although this method has been shown to be an
effective way to prevent GVHD [3,14], details about the need
for complement, optimal antibody concentration, and cell
density in the suspension are not known. The current study
was designed to optimize the conditions for ex vivo immu-
nodepletion of allogeneic grafts harvested for transplantation.
METHODS
Cell Samples
Samples from healthy donors undergoing apheresis for the donation of
cytokine mobilized PBPCs were studied. Donors signed informed consent
forms approved by the ethics committee of the University of Cape Town and
Groot Schuur Hospital. The stem cell mobilization strategy was with ﬁl-
grastim at 5 to 10 mg/kg on each of 5 consecutive days. Apheresis of PBPCwas
performed with a Cobe Spectra (Gambro, Lakewood, CO), and, once
completed, aliquots for the study were then drawn from the harvest bag
containing sodium citrate and processed on the same day.
Cell Treatments
From the aliquot, a sample was collected into vacutainers containing
EDTA, and the mononuclear cells were separated by Ficoll density centri-
fugation (1.077 g/mL, Histopaque; Sigma-Aldrich Johannesburg, South
Africa) at 400 g, and residual red cells were removed with ammonium
chloride. Cells were washed in PBS, enumerated using an automated particle
counter (model Zf; Coulter Electronics, Hialeah, FL), and resuspended at the
various working solutions.
Treatment of cells was as follows. First, 5  106 cells/mL resuspended in
Iscove’s modiﬁed Dulbecco’s medium (IMDM) þ 10% AB serum (Gibco Life
Technologies, Austin, TX) were incubated with varying doses of commer-
cially obtained alemtuzumab (Genzyme, Sanoﬁ, France) (0, .00001, .0001,
.001, and .01 mg/mL) for 30 minutes at room temperature. Second, varying
concentrations of cells (1 106, 5 106, and 10 106 cells/mL) resuspended
in IMDM þ 10% AB serum were incubated with .001 mg/mL alemtuzumab
for 30 minutes at room temperature. Finally, to analyze the effect of
complement on cell lysis, experiments were performed with the addition of
fresh or heat inactivated AB serum (10%).
After incubation, cells were pelleted at 2000 rpm for 10 minutes at 4C,
and the supernatants were removed and stored at 80C until use in ELISA.
The pelletedmononuclear cells were resuspended in 1 mL PBS, and after the
total white cell count was enumerated, individual cell populations were
analyzed using standard ﬂow cytometry.
Flow Cytometry
The composition of the nucleated population in the graft was deﬁned
immunophenotypically before Ficoll separation and before and after
coculture of cells with alemtuzumab. This was achieved using a standard 4-
color ﬂow cytometric protocol. Brieﬂy, 100 mL of the cell suspension was
incubated with the relevant antibody combination for 20 minutes at room
temperature. Thereafter, cells were washed and, after reconstitution with1 mL PBS, analyzed using a Facs-Calibur ﬂow cytometer (Becton Dickinson-
Biosciences, UK, New Jersey).
CD45-Allophycocyanin was used as a backbone marker to gate all
nucleated hemopoietic cells. These included granulocytes, monocytes,
lymphocytes, and other progenitors. The following ﬂuorescent conjugated
antibodies were used to analyze the various cell populations: CD3PE,
CD4PECy7, CD8PECy7, CD13PE, CD14 PECy7, CD33PE, CD22b PECy7, CD34PE,
CD19PECy7, CD56PE, and CD16PECy7. All antibodies were purchased from
Becton Dickinson (BD-Biosciences), and a relevant isotypic control was used
to identify any nonspeciﬁc binding of the antibody. In addition, the
expression of the CD52 antigen on the surface of the cells was determined
using FITC-conjugated anti-human CD52 (Dako, Glostrup, Denmark). The
mean ﬂuorescent intensity (MFI) was recorded both before and after the
cells were incubated with alemtuzumab. The absolute count of each cell
population was calculated using the total white blood cell count in the
sample, and the results were recorded on an Excel spreadsheet. The absolute
number of CD34þ cells was determined using the Stem-Kit CD34þ HPC
enumeration set (Beckman Coulter, Life Sciences, Lakeview, IN). The kit uses
a sequential gating strategy recommended by International Society of
Hematotherapy and Graft Engineering guidelines and ﬂuorescent beads to
calculate the absolute number of events carrying the antibodies [19].
Measurement of Alemtuzumab Using ELISA
After dose response studies with alemtuzumab, supernatant samples
were collected and stored at 80C until analysis by ELISA. Test cell-free
samples were incubated at 56C for 30 minutes to inactivate complement.
The adopted method was based on the assay developed by Jilani et al. [20].
Costar ﬂat-bottom 96-well EIA/RIA immunoplates (Corning Lifesciences,
Tewsbury, MA) were coated with 2 mg/mL afﬁnity-puriﬁed, human absor-
bed, rabbit anti-rat IgG (HþL; Southern Biotech, Birmingham, AL) in .05 M
carbonate-bicarbonate buffer, pH 9.4 (100 mL/well) and incubated overnight
at 4C. After washing 5 times with PBS-Tween 20 buffer (1  PBS, pH 7.2
containing .01% Tween 20), plates were blocked with 300 mL/well of BSA
(2%) in PBS-Tween 20 buffer overnight at 4C. Plates were then washed 3
times as described above, and alemtuzumab standards (diluted in IMDM þ
10% AB serum) and test samples were added to the plates. Each standard and
test serum sample was assayed in triplicate and incubated overnight at 4C.
Plates were washed 5 times as described above and 100 mL/well of
a 1:50,000 dilution of peroxidase-conjugated afﬁnity-puriﬁed rabbit anti-
human-Fc (Pierce, ThermoScientiﬁc, Separations, Inqaba Biotechnical
Industries, Pretoria, South Africa) in PBS-Tween 20 buffer was added. Plates
were incubated for 1.5 hours at room temperature with constant shaking
and washed 5 times. For detection, 100 mL/well of tetramethylbenzidine
substrate (Thermo, Inqaba Biotechnical Industries, Pretoria, South Africa)
was used. Plates were incubated at room temperature for 10 minutes, and
100 mL/well of 1 M HCl was added to stop the reaction. Absorbance was read
at 450 nm, and a log reading of samples against standards was calculated.
In Vitro Culture Assay
To determine viability and clonogenic growth of CD34þ cells, mono-
nuclear cells that had been exposed to alemtuzumab were incubated for 2
hours on a plastic Petri dish and nonadherent cells eluted. Nonadherent
mononuclear cellswere incubatedwith Dynabeads (Life Technologies, Austin,
TX) attached to anti-CD34 antigen following the manufacturer’s recom-
mended protocol and the CD34þ population selected with a magnet. Cells
were freed from the beads with Detachabead (Dyna; Life technologies, New
York) reagent. One to 5103 CD34þ cellswere incubated in IMDMcontaining
10 ng/mL IL-3 and granulocyte colony-stimulating factor, 20% FCS (Highveldt,
Johannesburg, South Africa) in 20% methylcellulose. Aggregates containing
more than 40 cells were scored to compare colony numbers of samples
exposed to the working concentration of alemtuzumab and control cultures.
Statistical Analysis
Descriptive statistics included absolute and relative frequencies for cate-
gorical, mean, standard deviation, median, and range for numeric values.
Because of the skewed distribution of variables, the Mann-Whitney U test or,
in case of more than 2 groups, the Kruskal-Wallis test were applied for
conﬁrmatory group comparisons concerning antibody-induced cytotoxic cell
activity. The level of signiﬁcance was <.05 (2 sided). Calculations were per-
formedusing commercial Statistica 10 software (StaSoft, Hamburg, Germany).
RESULTS
Evaluation of Mononuclear Cell Numbers and CD52
Expression
Filgrastimmobilized PBPCs of 6 healthy transplant donors
were collected for this study. The median mononuclear
(blast þ monocytes þ lymphocytes) cell number in the
Table 1
Median Percent, Absolute Number, and MFI of CD52 Expression of the Cell Populations under Study
CD3 CD4 CD 8 CD19 CD56 CD16 CD13 CD33 CD14 CD11b CD34
Percent 14.39 7.99 3.24 .523 1.35 44.47 64.77 34.24 31.01 51.05 1.96
Absolute number .61 .34 .15 .023 .063 1.92 2.857 1.5 1.39 2.24 .1
CD52 MFI 329.14 313.57 298.71 559.13 732.69 208.06 86.76 193.67 5.38 169.04 3.45
Cells were exposed at different cell numbers to various concentrations of alemtuzumab in the presence or absence of complement. Data represent the median
values of 5 experiments.
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Thereafter, mononuclear cells were separated by Ficoll
density centrifugation and then quantiﬁed. Using 4-color
ﬂow cytometry, the absolute number and percentage of
T cells (CD3, CD4, and CD8), B cells (CD19), myeloid cells
(CD13, CD33), monocytic cells (CD14, CD11b), natural killer
(NK) cell (CD56), and clonogenic cells (progenitors [CD34þ])
were determined from each sample. Table 1 shows the
median percentage, absolute number, and MFI for CD52 for
the various cell subsets and highlights that the median
ﬂuorescence intensity was signiﬁcantly lower in myeloid and
CD34þ cells than on lymphocytes (P < .01).Figure 1. Dose ranging study with alemtuzumab on the lymphoid cell populations. T
alemtuzumab concentrations, whereas the y axis shows the resulting cell numbers a
and particularly of T cells at .001 mg/mL. Further increases in the antibody concentraEffect of Alemtuzumab on Mononuclear Blood Cells
Mononuclear cell suspensions containing 5106 cells/mL
were incubated with .00001, .0001, .001, and .01 mg alem-
tuzumab for 30 minutes at 20C. Cells were washed and
analyzed by ﬂow cytometry again to quantitate the remain-
ing cell proportions. Figure 1 shows that the total cell
number, T cell, B cell, myeloid cell, and NK cell populations
declined in a dose-dependent fashion after exposure of the
cells to alemtuzumab. Although total cell number decreased
by 50%, this was moremarked in the T cell population, where
a 2 log reduction of CD3þ cells was observed. The CD4þ
population appeared to be particularly sensitive to thehe antibody was incubated with 5  106 cells in 1 mL. The x axis depicts the
fter the incubation. The bar graphs show signiﬁcant reduction in cell numbers
tion did not lead to greater immunodepletion.
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shows that although myeloid and monocytic cells (CD13þ,
CD14þ, and CD33þ) were also depleted, the decline in
numbers was lower and had not reached a plateau level, even
at the highest antibody concentration.
To determine if complement had a beneﬁcial effect on the
cytotoxic activities of alemtuzumab, mononuclear cells were
incubated with or without 10% fresh AB serum (as source of
complement). In addition, to determine if cell concentration
increased the cytotoxic effect of the antibody, cells were
exposed to the antibody and fresh serum at 1, 5, and 10 106/
mL. Figure 3 shows a signiﬁcant cell number reduction for
CD3þ, CD4þ, CD8þ, and CD19þ cells with alemtuzumab, but
the maximum effect was in the presence of serum/comple-
ment and when the highest cell concentration was used.
From Figure 3, it can also be observed that maximum cell
depletion reached a plateau at .001mg/mL for both CD4 and
CD8 cells.Figure 2. Dose ranging study with alemtuzumab on the myeloidemonocytic and CD3
x axis depicts the alemtuzumab concentrations, whereas the y axis shows the resultin
to reduction in the number of myeloid and monocytic cells at all the concentrationsFinally, Figure 4 shows the effect of all 4 test concentra-
tions of alemtuzumab on the generation of granulocyte-
macrophage colony-forming unit, conﬁrming that the
antibody appears to be nontoxic to clonogenic precursors.
The reduction in CD34þ cell numbers seen in Figure 2 is
likely to represent depletion of other lineage restricted
precursors but not of clonogenic myeloid progenitors.
Alemtuzumab Supernatant Levels
Mononuclear cells were exposed at the working concen-
tration of .001 mg/mL alemtuzumab in cell number dose
response studies. Mononuclear cells were suspended at 1, 5,
and 10  106 cells/mL in PBS in the presence of 10% fresh AB
serum and alemtuzumab. Controls without cells, serum, or
alemtuzumabwere included with each run. Optical densities
of log values of the working concentrations of alemtuzumab
were plotted on a graph, and a standard curve was drawn
from the control samples. A representative standard curve, as4þ cell populations. The antibody was incubated with 5  106 cells in 1 mL. The
g cell after incubation. Incubation of mononuclear cells with alemtuzumab led
tested.
Figure 3. Mononuclear cells were incubated with alemtuzumab and fresh AB serum at 1, 5, and 10  106 cells/mL. Control and alemtuzumab tests contained IMDM
only. The presence of AB serum at the highest cell concentration led to the greatest lymphocyte reduction, particularly of CD 4 cells. ***P < .01, **P < .05.
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Figure 5. Dilutions of alemtuzumab in the range of .1 to 10-7
mg/mL are shown, and log readings of samples against
control were derived from the standard curve. Studies were
performed in triplicate, and results were expressed as
median values. The values of 4 different samples were
correlated with their standard curves, and results were ob-
tained at 3 cell number concentrations. As shown in Figure 6,
a signiﬁcant reduction in the residual concentration ofFigure 4. Effect of alemtuzumab on clonogenic progenitor cells. CD34þ cells
were selected with immunomagnetic beads and cultured in methyl cellulose
containing IL-3 and granulocyte colony-stimulating factor for 14 days with
incremental concentrations of alemtuzumab. No difference in the colony
number was seen at any antibody dose.alemtuzumab was observed in the cell supernatants at the 2
higher cell numbers, suggesting that ex vivo alemtuzumab is
depleted by cells and the free concentration drops below the
level of detection at 5  106 cells/mL.DISCUSSION
This study sought to determine the in vitro effects of
alemtuzumab when used for the immune manipulation of
donor grafts for transplantation [2,3]. Speciﬁcally, we tried to
deﬁne the optimal ex vivo conditions for the predictable
depletion of immune cells in stem cell grafts including
antibody concentration, the need for complement, and theFigure 5. Representative standard curve of alemtuzumab concentrations
between .1 and 10-7 mg/mL, with standard errors shown on the x axis. The y
axis represents mean corrected absorbance (optical density) measured at 450
nm for the stated alemtuzumab concentrations on the x axis. The values were
used to calculate alemtuzumab supernatant levels in donor samples.
Figure 6. Cell numbers and residual concentration of alemtuzumab in
supernatant. Alemtuzumab at .001 mg/mL was added to 1, 5, and 10  106
mononuclear cells as shown on the x axis. The y axis shows the remaining
alemtuzumab concentration in mg/mL. At the 2 highest cell numbers, the
concentrations of alemtuzumab is signiﬁcantly lower (P < .01 and <.05).
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graft.
Alemtuzumab is a recombinant humanized monoclonal
IgG1 antibody directed against the CD52 antigen, a 12 amino
acid glycosylated glycosylphosphatidylinositol-linked cell
surface protein [9]. The function of CD52 remains largely
unknown, but it is expressed on more than 95% of peripheral
blood cells, includingNKanddendritic cells [7,21]. Depending
on experimental conditions, in vitro studies have found
prominent killing via the complement pathway [22,23],
a strong ADCC through a caspase-dependent pathway or
a direct caspase-independent apoptotic pathway [24-26]. The
CD52 cell membrane antigen density is higher on normal T
lymphocytes than on normal B lymphocytes and myeloid
cells. These differences in CD52 expression may explain
differential sensitivity of cells to alemtuzumab both in vitro
and in vivo [15]. In vivo in a human CD52-transgenic mouse,
a major role for ADCC in lymphocyte depletion has been
shown, with neutrophils and NK cells as potential effectors
[27]. Although NK cells are also depleted by alemtuzumab,
they tend to recover rapidly after infusion of the graft [28].
Although the mechanisms of action of alemtuzumab are
relatively well understood, the best method of depletion
(in vivo or ex vivo) or the optimal dose of antibody for GVHD
prevention is not known. When cells are incubated ex vivo,
because many nonimmune cells in the PBPC graft express
CD52, the antibody binding to the target may result in anti-
body depletion with inadequate lymphocyte purging and no
free alemtuzumab detectable in the PBPC infusion bag. On
the other hand, if excess alemtuzumab is administered,
unbound antibody within the graft may lead to problems
associated with the in vivo treatment, including delayed
immunosuppression caused by ongoing antibody-mediated
killing of thymic emigrants. Thus, because graft cells
express different densities of the CD52 antigen on cell
membranes, the optimal cell concentration and dose of
antibody required to effectively deplete the immune system
remain unknown.In this study, we not only investigated the main mecha-
nism of Campath 1Hemediated killing of CD4þ and CD8þ
T cells in PBPC grafts but also studied the effect of the
differential CD52 expression on cell subtypes in the graft.
Table 1 shows that cell killing in the PBPC sample is directly
related to ﬂuorescence intensity (and expression of CD52
target epitope numbers), which is highest in CD4 cells, lower
in CD8 cells, and lowest in monocytes and granulocytes.
Figure 1 shows that incubation of PBPCs with alemtuzumab
at .001 and .01 mg/mL led to a signiﬁcant (>1 log) reduction
of T cell numbers. The degree of ADCC was essentially the
same for CD4þ and CD8þ T cells, whereas the addition of
fresh AB serum as a source of complement resulted in a more
intense depletion in CD4 but not CD8 cells. Similar obser-
vations were made by other investigators [26]. Although
higher antibody concentrations had no further impact on
lymphocyte killing, no plateau in cell death was seen in the
myeloidemonocytic series even at the highest antibody
concentration per dose (Figure 2).
Our results show that alemtuzumab depletes most CD52-
expressing cells present in the blood of stem cell transplant
harvests. In the presence of complement and at the highest
mononuclear cell concentration of 10  106 cells/mL, there
was an excess of 3-log reduction of the CD4 population. This
may be related to higher CD52 expression on B and T cells
than on myeloid cells (as demonstrated by MFI shown in
Table 1). The dose cell response study showed even greater
CD4 and CD8 killing at higher cell numbers, reaching 3-log
depletion of the T helper cells with the addition of comple-
ment (Figure 3). This is important because, occasionally,
when there is a major blood group difference between the
donor and recipient, manipulation of the graft is necessary. If
plasma depletion is required, cells should be resuspended in
fresh AB plasma to ensure an adequate complement effect. Of
relevance, although CD34þ cells may express CD52, Figure 4
shows that even at the highest alemtuzumab concentration
there is no loss of clonogenic activity of selected CD34þ
progenitors.
A recent study showed that lymphocyte killing in the
circulation is less effective than in vitro, but clinical studies
with alemtuzumab conﬁrm intense and prolonged immu-
nosuppression [21]. A possibility is that in vivo, T cell killing
takes place more efﬁciently in organs outside the circulation,
such as in the spleen, liver, or lymph nodes, where similar
close interaction takes place. However, lymphoid organs
have variable abilities to mediate ADCC and some (eg, the
spleen) may be more efﬁcient than others [29]. To this effect
and to determine the presence of soluble alemtuzumab in
the suspension, the residual antibody levels in the graft were
determined by ELISA. Figure 5 shows the standard curve
conﬁrming that the antibody was detectable at the working
concentrations. Figure 6 shows a graph derived from the cell
dose response experiments at a ﬁxed concentration of anti-
body and illustrates that at .001 mg/mL (maximal cell kill
effect), as cell numbers were increased alemtuzumab was
further consumed and that no free antibody was identiﬁed
within the limit of detection of this assay.
These observations allow us to derive calculations that
suggest an adequate graft should be resuspended at a ratio of
10  109 cells in a ﬁnal volume of 100 mL containing 1 mg
alemtuzumab. Based on these estimates, the median dose of
alemtuzumab added to the grafts (which had a median of
81%mononuclear cells or 6.51010 cells [range, 2 to 11]) was
7 mg. However, a more precise evaluation will only be
possible in a prospective study that should also include ﬂow
N. Novitzky et al. / Biol Blood Marrow Transplant 19 (2013) 1753e1759 1759cytometric assessment of the level of immunodepletion of
the graft and determination of the presence of free antibody
in the graft supernatant by ELISA.
This work can be summarized by the following conclu-
sions. First, alemtuzumab “in the bag” is effective at the cell
concentration of .001 mg/mL (containing 10  106 mono-
nuclear cells), and the addition of higher doses into the graft
is unnecessary. Second, there should be an adequate supply
of plasma to allow sufﬁcient complement-dependent cell
cytotoxicity. Third, a higher cell concentration leads to
greater target cell killing so that the immunodepleting effect
is mainly (if not solely) ex vivo and a minimal amount of
residual free antibody is infused to the patient. We are
currently testing these assumptions in a prospective study
where these conditions are replicated, determining evidence
of free alemtuzumab in the graft and correlating the results
with early immune reconstitution rate in the patient.
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